MAJESTEC-9 Trial

A Progression-free Survival 100 18-mo Progression-free survival 80 69.8 (95% CI, 63.7-75.1) Percentage of Patients 60 Teclistamab 40 20 PVd or Kd 26.9 (95% CI, 21.1-33.0) 0 0 3 6 9 12 15 18 21 24 27 30 Months since Randomization --- 100 Teclistamab 18-mo Overall survival 79.2 (95% CI, 73.5-83.8) 80 Percentage of Patients Alive PVd or Kd 60 68.6 (95% CI, 62.4-74.0) 40 20 Hazard ratio for death, 0.60 (95% CI, 0.43-0.83) P=0.002 0 0 3 6 9 12 15 18 21 24 27 30 Months since Randomization --- Event Onset Time >6-≤12 >12-≤18 >18-≤24 Total ≤6 Months >24 Months Months Months Months Teclistamab Infections and infestations Patients within window, no. 291 291 237 169 102 33 Patients with ≥1 grade ≥3 123 (42.3) 96 (33.0) 33 (13.9) 15 (8.9) 9 (8.8) 3 (9.1) treatment-emergent infections and infestations, no. (%)

MajesTEC-9: Key Takeaways 1 2 3 Second positive phase 3 study with Tec-based therapy Tec monotherapy significantly The safety profile of Tec was showing significant PFS and improved PFS (HR, 0.29) and consistent with the known OS benefit in 2L+ RRMM os (HR, 0.60) vs PVd/Kd profile Significant PFS and OS advantage seen in MajesTEC-9, as well as MajesTEC-3,¹ support Tec-based therapy as a new 2L+ SOC across practice settings 1. Costa LJ, et al. N Engl J Med. 2026;394(8):739-752 2L+, second-line or higher; HR, hazard ratio; Kd, carfilzomib and dexamethasone; OS, overall survival; PFS, progression-free survival; PVd, pomalidomide, bortezomib, and dexamethasone; RRMM, relapsed refractory multiple myeloma; SOC, standard-of-care; Tec, teclistamab. 2 Presented by R Mina at the American Society of Clinical Oncology (ASCO) Annual Meeting: May 29-June 2, 2026; Chicago, IL, USA --- MajesTEC-9: Phase 3 Study Design Primary endpoint Key inclusion criteria Tec PFS per IRC RRMM n=296 Key secondary endpoints 1-3 prior LOTs including an anti-CD38 mAb >CR and lenalidomide 1:1 OS ECOG PS score of 0-2 randomization MySIm-Q total symptom score N=593 Other secondary endpoints Key exclusion criteria PVd/Kd April 28, 2023- ORR Prior BCMA-directed therapy April 3, 2025 by investigator's choice Safety n=297 (69% Kd) PK and immunogenicity Exploratory endpoints MRD-negative >CR (10-5) SUD 28-day cycles Tec 1.5 mg/kg C1 QW C2 QW C3-C6 Q2W C7+ Q4W Tec 3 mg/kg D1 D3 D5 D12 D19 D1 D8 D15 D22 D1 D8 D15 D22 D1 D8 D15 D22 Tec SC Dex (pre-med)* Monthly Tec dosing from C7 (earlier if ≥VGPR); steroid free after C1D5 *Administered per the approved schedules. Kd was administered either twice weekly (20/56 mg/m/) or once weekly (20/70 mg/m/) depending on the local clinical practice. "Disease progression and response were assessed by an IRC per IMWG 2016 criteria. Patients received SUD of 0.06 mg/kg and 0.3 mgkg on D1 and 03, respectively. Patients with confirmed WGPR could which to dosing Q4W earlier than C7 per investigator's discretion *Dex, acetaminophen, and diphenhydramine pre-med was required on C1 D1. 03. and DS. c. Cycle CR, complete response; D. Day Dex, dexamethasone; ECOG P.S. Eastem Cooperative Oncology Group performance status; MWG, International Myeloma Working Group: IRC, independent review committee; MRD, minimal residual disease; MySim-Q, Multiple Myeloma Symptom and Impact Questionnaire ORR, overall response rate: PK, pharmacokinetics; pre-med, pre-medication; QW, weekly; Q2W, every 2 weeks; CHW, every 4 weeks; SC, subcutaneous, SUD, step-up dosing VGPR very good partial response. Presented by R Mina at the American Society of Clinical Oncology (ASCO) Annual Meeting: May 29-June 2. 2026 Chicago, L USA --- MajesTEC-9: Baseline Demographic and Disease Characteristics Tec PVd/Kd Tec PVd/Kd Characteristic Characteristic (n=296) (n=297) (n=296) (n=297) Age Baseline ECOG PS score, n (%) Median (range), years 70 (34-85) 70 (36-86) 0 156 (52.7) 135 (45.5) >75 years, n (%) 84 (28.4) 89 (30.0) 1 121 (40.9) 137 (46.1) Sex, n (%) 2 19 (6.4) 24 (8.1) 3 0 Male 150 (50.7) 153 (51.5) 1 (0.3) Female 146 (49.3) ISS stage, n (%) 144 (48.5) I 168 (56.8) 170 (57.2) Race, n (%) II 86 (29.1) 82 (27.6) White 190 (64.2) 198 (66.7) III 42 (14.2) 45 (15.2) Asian 62 (20.9) 56 (18.9) BMPCs >60%,b n/N (%) 31/292 (10.6) 40/295 (13.6) Black or African American 10 (3.4) 10 (3.4) Soft-tissue plasmacytomas, n (%) 54 (18.2) 65 (21.9) Other 34 (11.5) 33 (11.1) Extramedullary plasmacytomas© 19 (6.4) 22 (7.4) Paraskeletal plasmacytomasᶜ 43 (14.5) 52 (17.5) High-risk cytogenetics,d n/N (%) 105/294 (35.7) 104/296 (35.1) Balanced baseline characteristics are reflective of a RRMM population, including high-risk disease "Other" includes American Indian or Alaska Native (Tec, n=2 [0.7%]; PVd/Kd, n=0), not reported (Tec, n=18 [6.1%]: PVd/Kd, n=23 [7.7%]). unknown (Tec, n=7 [2.4%]: PVd/Kd, n=6 [2.0%]), and multiple (Tec, n=7 [2.4%]; PVd/Kd, n=4 [1.3%]). Maximum value from bone marrow biopsy or bone marrow aspirate was selected if both results were available. A patient may have both extramedullary and paraskeletal plasmacytomas. Presence of 21 of del(17p). t(4;14). or t(14;16). BMPC, bone marrow plasma cell; ISS, International Staging System. From The New England Journal of Medicine, Touzeau C, et al., Teclistamab in Multiple Myeloma with One to Three Previous Lines of Therapy. Copyright © 2026 Massachusetts Medical Society. Adapted with permission from Massachusetts Medical Society. 5 Presented by R Mina at the American Society of Clinical Oncology (ASCO) Annual Meeting: May 29-June 2, 2026; Chicago, IL, USA --- MajesTEC-9: Prior LOTs Tec PVd/Kd Characteristic Tec PVd/Kd (n=296) (n=297) Characteristic (n=296) (n=297) Prior LOTs, n (%) Refractory status, n (%) Median (range), n 2 (1-3) 2 (1-3) To last prior LOT 274 (92.6) 273 (91.9) 1 prior LOT 64 (21.6) 64 (21.5) Any PI 122 (41.2) 128 (43.1) 2 prior LOTs 131 (44.3) 137 (46.1) Any IMiD 245 (82.8) 251 (84.5) 3 prior LOTs 101 (34.1) 96 (32.3) Lenalidomide Prior transplantation, n (%) 145 (49.0) 147 (49.5) 234 (79.1) 240 (80.8) Autologous 145 (49.0) 146 (49.2) Any anti-CD38 253 (85.5) 252 (84.8) Prior therapy exposure, n (%) Double refractory (IMiD and anti-CD38) 218 (73.6) 221 (74.4) PI 256 (86.5) 254 (85.5) Triple refractory (IMiD, anti-CD38, and PI) 102 (34.5) 98 (33.0) IMID 296 (100) 297 (100) Anti-CD38 296 (100) 297 (100) Approximately 75% of patients were double refractory to an IMiD and anti-CD38 mAb IMD, immunomodulatory drug; PI, proteasome inhibitor. From The New England Journal of Medicine, Touzeau C, et al., Teclistamab in Multiple Myeloma with One to Three Previous Lines of Therapy. Copyright © 2026 Massachusetts Medical Society. Adapted with permission from Massachusetts Medical Society. 6 Presented by R Mina at the American Society of Clinical Oncology (ASCO) Annual Meeting: May 29-June 2, 2026; Chicago, IL, USA.

MajesTEC-9: Phase 3 Study Design Primary endpoint Key inclusion criteria Tec PFS per IRC RRMM n=296 Key secondary endpoints 1-3 prior LOTs including an anti-CD38 mAb >CR and lenalidomide 1:1 OS ECOG PS score of 0-2 randomization MySim-Q total symptom score N=593 Other secondary endpoints Key exclusion criteria PVd/Kd* April 28, 2023- ORR Prior BCMA-directed therapy April 3, 2025 by investigator's choice Safety n=297 (69% Kd) PK and immunogenicity Exploratory endpoints MRD-negative >CR (10-5) SUD 28-day cycles Tec 1.5 mg/kg C1 QW C2 QW C3-C6 Q2W C7+ Q4W Tec 3 mg/kg D1 D3 D5 D12 D19 D1 D8 D15 D22 D1 D8 D15 D22 D1 D8 D15 D22 Tec SC Dex (pre-med)* Monthly Tec dosing from C7 (earlier if ≥VGPR); steroid free after C1D5 *Administered per the approved schedules. Kd was administered either twice weekly (20/56 mg/ml) or once weekly (20/70 mg/ml) depending on the local clinical practice. *Disease progression and response were assessed by an RC per IMWG 2016 criteria. Patients received sup of 0.00 mg/kg and 0.3 mgkg on D1 and 03, respectively Patients with confirmed WGPR could switch to dosing Q4W earler than C7 per investigator's discretion *Dex, acetaminophen, and diphenthydramine pre-med was required on C1 D1. 03. and D5. c, Cycle CR, complete response; D. Day Dex, diceamethasone; ECOG P.S. Eastern Cooperative Oncology Group performance status; MWG, International Mysicms Working Group IRC, independent review committee; MRD, minimal residual disease; MySim-Q. Multiple Myeloma Symptom and impact Questionnaire ORR, overall response - PK, pharmacokinetics; pre-med, pre-medication CW, weekly, Q2W, every 2 weeks; CHW, every 4 weeks; SC, subcutaneous, SUD. step-up dosing VGPR very good partial response. Presented by R Mina at the American Society of Clinical Onoology (ASCO) Annual Meeting: May 29-June 2. 2020. Chicago, L USA --- MajesTEC-9: Tec Significantly Improved PFS (Primary Endpoint) Estimated 18-mo PFS 100 Surviving without progression, % 80 69.8% 60 Tec Median, NR 40 26.9% 20 PVd/Kd HR, 0.29 (95% CI, 0.23-0.38); P<0.0001ᵃ Median, 8.2 months Median follow-up: 17.3 months 0 0 3 6 9 12 15 18 21 24 27 30 Months No. at risk Tec 296 258 239 206 172 141 92 57 27 6 0 PVd/Kd 297 199 162 112 74 51 33 16 6 1 0 Tec significantly improved PFS, with a 71% reduction in the risk of disease progression or death in a highly refractory population *The P value crossed the prespecified stopping boundary for superiority for the first interim analysis (P=0.0197). CI, confidence interval; NR, not reached. From The New England Journal of Medicine, Touzeau C, et al., Teclistamab in Multiple Myeloma with One to Three Previous Lines of Therapy. Copyright c 2026 Massachusetts Medical Society. Adapted with permission from Massachusetts Medical Society. 8 Presented by R Mina at the American Society of Cinical Oncology (ASCO) Annual Meeting: May 29-June 2, 2026; Chicago, L, USA. --- MajesTEC-9: Tec Significantly Improved OS Estimated 18-mo OS 100 79.2% Tec 80 Median, NR Surviving, % 60 68.6% PVd/Kd Median, NR 40 20 HR, 0.60 (95% CI, 0.43-0.83); P=0.0020 Median follow-up, 17.3 months 0 0 3 6 9 12 15 18 21 24 27 30 No. at risk Months Tec 296 280 263 237 195 159 107 66 33 11 0 PVd/Kd 297 264 243 210 172 137 91 54 25 8 0 Tec significantly improved OS vs PVd/Kd, despite over two-thirds of PVd/Kd patients who initiated subsequent therapy receiving a BsAb or CAR-T BsAb, bispecific antibody; CAR-T, chimeric antigen receptor T cell. From The New England Journal of Medicine, Touzeau C, et al., Teclistamab in Multiple Myeloma with One to Three Previous Lines of Therapy. Copyright c 2026 Massachusetts Medical Society. Adapted with permission from Massachusetts Medical Society. 12 Presented by R Mina at the American Society of Clinical Oncology (ASCO) Annual Meeting: May 29-June 2. 2026; Chicago, IL, USA --- MajesTEC-9: Overall Safety Profile Tec (n=291) PVd/Kd (n=283) CRS mostly low grade; all resolved with no discontinuation TEAE, n (%)c Any grade Grade 3/4 Any grade Grade 3/4 Any TEAE 290 (99.7) 247 (84.9) 277 (97.9) 216 (76.3) Grade 1/2 (48.8%/16.5%), grade 3 (0.7%), no grade 4/5 Hematologic Neutropenia 182 (62.5) 158 (54.3) 81 (28.6) 63 (22.3) ICANS was infrequent, generally low grade Anemia 110 (37.8) 52 (17.9) 119 (42.0) 46 (16.3) Thrombocytopenia 80 (27.5) 31 (10.7) 110 (38.9) 60 (21.2) Grade 1/2 (2.4%/1.4%), grade 3 (0.3%)a Lymphopenia 71 (24.4) 59 (20.3) 49 (17.3) 32 (11.3) Nonhematologicᵃ Discontinuations due to TEAEs: 10.7% Tec VS 13.1% PVd/Kdb CRS 192 (66.0) 2 (0.7) 0 0 Diarrhea Death due to PD: 8.6% Tec VS 18.7% PVd/Kd 124 (42.6) 15 (5.2) 72 (25.4) 4 (1.4) Cough 80 (27.5) 2 (0.7) 39 (13.8) 0 Grade 5 TEAEs: 6.5% Tec VS 3.5% PVd/Kd Injection-site erythema 71 (24.4) 0 8 (2.8) 0 Hypertension 20 (6.9) 13 (4.5) 51 (18.0) 32 (11.3) The safety profile was consistent with the known profile of Tec monotherapy "One patient had a grade 3 ICANS event that led to Tec discontinuation. Discontinuation of all components of study treatment. Most common TEAEs of any grade occurring in >20% of patients in either treatment group and the most common grade 3/4 TEAEs occurring in >10% of patients in either treatment group. "Hypogammaglobulinemia, URTI, and pneumonia were also reported but are discussed on the following summary of infections slide. CRS, cytokine release syndrome; ICANS, immune effector cell-associated neurotoxicity syndrome; TEAE, treatment emergent adverse event; URTI, upper respiratory tract infection. From The New England Journal of Medicine, Touzeau C, et al., Teclistamab in Multiple Myeloma with One to Three Previous Lines of Therapy. Copyright © 2026 Massachusetts Medical Society. Adapted with permission from Massachusetts Medical Society. 13 Presented by R Mina at the American Society . of Clinical Oncology . (ASCO) Annual Meeting: 1 May 29-June - . 2, 2026; Chicago, IL, USA

The NEW ENGLAND JOURNAL of MEDICINE ORIGINAL ARTICLE Teclistamab in Multiple Myeloma with One to Three Previous Lines of Therapy C. Touzeau,¹ R. Mina,²,³ H. Quach,⁴ V. Hungria,⁵ D. Bhutani, W. Chen,⁷ S. Kumar,⁸ C. Chaulagain,⁹ M.A. Dimopoulos, 10,11 N.J. Bahlis, 12 S. Maral,¹³ N.W.C.J. van de Donk,¹⁴ J. Schmidt Filho,¹⁵ K. Saja, 16 R. Teipel,¹⁷ M. Ando,¹⁸ W. Roeloffzen,¹ O. Annibali,²⁰ B. Augustson,² C. Botta,²² M. Delforge,²³ E. Bourgeois,² G. Buda,²⁵ M. Hus,26 A. Perrot,2 M. Preis,²⁸,²⁹ M. Beksac,³⁰ L. Pour,³¹ S. Farmer,³² M. Nunes,³³ A. Oriol, 34 T. Melchardt, 35 Y. Hu,³⁶³⁸ M. Flogegård,³⁹ D. Wang,⁴⁰ L. Pei,⁴⁰ S. Wroblewski,⁴ I.M. Ariës,⁴² N.A. Quijano Cardé,⁴¹ T. Perova, 41 T. de Jager,43 T.-M. Yeh,⁴⁰ V. Vanquickelberghe, P. Shah,⁴⁵ K. Chastain,⁴⁰ R. Kobos,⁴⁰ R. Carson,⁴¹ and O. Landgren,⁴⁶ for the MajesTEC-9 Trial Investigators*

MajesTEC-9: Overall Safety Profile Tec (n=291) PVd/Kd (n=283) CRS mostly low grade; all resolved with no discontinuation TEAE, n (%)c Any grade Grade 3/4 Any grade Grade 3/4 Any TEAE 290 (99.7) 247 (84.9) 277 (97.9) 216 (76.3) Grade 1/2 (48.8%/16.5%), grade 3 (0.7%), no grade 4/5 Hematologic Neutropenia 182 (62.5) 158 (54.3) 81 (28.6) 63 (22.3) ICANS was infrequent, generally low grade Anemia 110 (37.8) 52 (17.9) 119 (42.0) 46 (16.3) Thrombocytopenia 80 (27.5) 31 (10.7) 110 (38.9) 60 (21.2) Grade 1/2 (2.4%/1.4%), grade 3 (0.3%)a Lymphopenia 71 (24.4) 59 (20.3) 49 (17.3) 32 (11.3) Nonhematologicᵃ Discontinuations due to TEAEs: 10.7% Tec VS 13.1% PVd/Kdb CRS 192 (66.0) 2 (0.7) 0 0 Diarrhea Death due to PD: 8.6% Tec VS 18.7% PVd/Kd 124 (42.6) 15 (5.2) 72 (25.4) 4 (1.4) Cough 80 (27.5) 2 (0.7) 39 (13.8) 0 Grade 5 TEAEs: 6.5% Tec VS 3.5% PVd/Kd Injection-site erythema 71 (24.4) 0 8 (2.8) 0 Hypertension 20 (6.9) 13 (4.5) 51 (18.0) 32 (11.3) The safety profile was consistent with the known profile of Tec monotherapy "One patient had a grade 3 ICANS event that led to Tec discontinuation. Discontinuation of all components of study treatment. "Most common TEAEs of any grade occurring in >20% of patients in either treatment group and the most common grade 3/4 TEAEs occurring in >10% of patients in either treatment group. "Hypogammaglobulinemia, URTI, and pneumonia were also reported but are discussed on the following summary of infections slide. CRS, cytokine release syndrome; ICANS, immune effector cell-associated neurotoxicity syndrome; TEAE, treatment emergent adverse event; URTI, upper respiratory tract infection From The New England Journal of Medicine, Touzeau C, et al., Teclistamab in Multiple Myeloma with One to Three Previous Lines of Therapy. Copyright © 2026 Massachusetts Medical Society. Adapted with permission from Massachusetts Medical Society. 13 Presented by R Mina at the American Society of Clinical Oncology . (ASCO) Annual Meeting: May 29-June . 2, 2026; Chicago, IL, USA --- MajesTEC-9: Summary of Infections Tec (n=291) PVd/Kd (n=283) Hypogammaglobulinemia was common Any Grade Any Grade Grade 5 Grade 5 69.1% Tec and 50.2% PVd/Kd TEAE, n (%) grade 3/4 grade 3/4 Infections were more frequent when disease Any infection 241 (82.8) 121 (41.6) 16 (5.5) 193 (68.2) 82 (29.0) 8 (2.8) burden was high Most common infection or infestation Grade 5 infections: 16 (5.5%) with Tec VS URTI 77 (26.5) 7 (2.4) 0 58 (20.5) 6 (2.1) 0 8 (2.8%) with PVd/Kd Pneumonia 64 (22.0) 42 (14.4) 3 (1.0) 43 (15.2) 30 (10.6) 4 (1.4) 14/16 VS 8/8 in first 6 months COVID-19 45 (15.5) 10 (3.4) 1 (0.3) 22 (7.8) 3 (1.1) 0 5/16 VS 6/8 had no IgRT Nasopharyngitis 37 (12.7) 0 0 24 (8.5) 0 0 8/16 VS 2/8 had last IgG <400 mg/dL UTI 30 (10.3) 4 (1.4) 0 12 (4.2) 2 (0.7) 0 Grade 3/4 infections were frequent, reinforcing the need for diligent use of established IgRT and antimicrobial prophylaxis *Defined as occurring in >10% of patients in either treatment group. Defined as patients with 21 TEAE of hypogammaglobulinemia or a post-baseline IgG value <400 mg/dL IgG, immunoglobulin G; IgRT, immunoglobulin replacement therapy; UTI, urinary tract infection From The New England Journal of Medicine, Touzeau C, et al., Teclistamab in Multiple Myeloma with One to Three Previous Lines of Therapy. Copyright © 2026 Massachusetts Medical Society. Adapted with permission from Massachusetts Medical Society. 14 Presented by R Mina at the American Society of Clinical Oncology (ASCO) Annual Meeting: May 29-June 2, 2026; Chicago, IL, USA. --- MajesTEC-9: Grade ≥3 Infections Declined Over Time QW and Q2W Q4W Tec Tec dosing Tec dosing PVd/Kd 35 33.0 30 Percentage of patients with any onset of ≥1 grade ≥3 infections, % 25 23.3 20 15 13.9 14.7 9.1 10 8.9 8.8 9.1 7.5 5 0 0 ≤6 mo >6-512 mo >12-518 mo >18-524 mo >24 mo Tec (n/N)a 96/291 33/237 15/169 9/102 3/33 PVd/Kd (n/N)a 66/283 15/164 6/80 5/34 0/9 Grade ≥3 infections decreased from 6 months, consistent with disease control "Includes patients who are in the TEAE-reporting period for the specific window. Noting that patients are counted only once in a window for any given event, regardless of the number of times they actually experienced the event within the specific time window. 15 Presented by R Mina at the American Society of Clinical Oncology (ASCO) Annual Meeting; May 29-June 2, 2026; Chicago, IL, USA.

MajesTEC-9: Tec Significantly Improved OS Estimated 18-mo OS 100 79.2% Tec 80 Median, NR Surviving, % 60 68.6% PVd/Kd Median, NR 40 20 HR, 0.60 (95% CI, 0.43-0.83); P=0.0020 Median follow-up, 17.3 months 0 0 3 6 9 12 15 18 21 24 27 30 No. at risk Months Tec 296 280 263 237 195 159 107 66 33 11 0 PVd/Kd 297 264 243 210 172 137 91 54 25 8 0 Tec significantly improved OS vs PVd/Kd, despite over two-thirds of PVd/Kd patients who initiated subsequent therapy receiving a BsAb or CAR-T BsAb, bispecific antibody; CAR-T. chimeric antigen receptor T cell. From The New England Journal of Medicine, Touzeau C, et al., Teclistamab in Multiple Myeloma with One to Three Previous Lines of Therapy. Copyright c 2026 Massachusetts Medical Society. Adapted with permission from Massachusetts Medical Society. 12 Presented by R Mina at the American Society of Clinical Oncology (ASCO) Annual Meeting: May 29-June 2. 2026; Chicago, IL, USA.

cancernetwork® home of the journal ONCOLOGY 3 ABSTRACTS TO WATCH ASCO 2026 I Multiple Myeloma Abstract 7507 MajesTEC-9 Phase 3: Teclistamab monotherapy vs PVd/Kd in relapsed/refractory multiple myeloma (1-3 prior lines) Presenter: Roberto Mina, MD Abstract 7510 Optec/Optal Phase 2: Outpatient teclistamab or talquetamab with prophylactic tocilizumab in RRMM Presenter: Peter Forsberg, MD Abstract LBA7506 SUCCESSOR-2 Phase 3: Mezigdomide + carfilzomib + dexamethasone (Mezikd) vs Kd in RRMM Presenter: Paul G. Richardson, MD Read more on CancerNetwork.com

® ASCO® #ASCO26 Abstract #7507 Oral Abstract Session AMERICAN SOCIETY OF CLINICAL ONCOLOGY KNOWLEDGE CONQUERS CANCER MajesTEC-9 Teclistamab Tec VS PVd/Kd in RRMM BCMAxCD3 after 1-3 prior lines bispecific antibody FIRST phase 3 study showing superior PFS & OS with Tec monotherapy in anti-CD38/LEN-exposed RRMM. @DrRishabhOnco KEY EFFICACY RESULTS PFS (Primary Endpoint) OS (Secondary Endpoint) ≥CR RATE HR HR 0.29 0.60 65.9% vs 16.8% Tec PVd/Kd (95% CI, 0.23-0.38) (95% CI, 0.43-0.83) Benefit consistent P < 0.0001 P = 0.0020 across key subgroups: 18-MONTH PFS RATE 18-MONTH OS RATE Anti-CD38 refractory 69.8% vs 26.9% 86.8% 75.7% Len refractory vs All prior LOT subgroups Tec PVd/Kd Tec PVd/Kd SAFETY SNAPSHOT CRS ICANS Grade 3/4 infections 66% 4.1% higher with Tec (Grade 1/2: 48.8% / 16.5%) (Grade 1/2: 2.4% / 1.4%) TAKEAWAY Tec monotherapy significantly improves PFS and os vs standard of care with manageable safety in anti-CD38/LEN-exposed RRMM. These phase 3 results support Tec-based regimens as early as second line.

ASCO 2026 UPDATE Majes TEC-9 Trial Teclistamab VS PVd/Kd in Relapsed/Refractory Multiple Myeloma MV Onco 01 Earlier Relapse Remains Challenging Many RRMM patients now exposed BCMA to anti-CD38 + lenalidomide Early relapse outcomes remain poor Plasma T cell cell Teclistamab evaluated earlier than prior studies First phase 3 trial of teclistamab monotherapy in 1-3 prior lines 02 Simple Phase 3 Design Teclistamab VS PVd/Kd 593 patients 1-3 prior lines Mostly refractory disease 03 A Difficult-to-Treat Population 80% 85% 92% Len refractory Anti-CD38 refractory Refractory to last therapy Reflects modern real-world early relapse RRMM 04 Clear PFS Advantage Teclistamab markedly prolonged progression-free survival Median PFS: 18-month PFS: HR 0.29 Not reached 69.8% VS 26.9% vs 8.2 months 05 Overall Survival Improved OS benefit persisted despite substantial subsequent anti-BCMA therapy in the control arm HR 0.60 Among control-arm patients receiving subsequent therapy, 68.4% later received BsAb or CAR-T therapy Suggests meaningful early-line benefit with teclistamab 06 Deeper and More 07 Expected Immune Toxicities Durable Responses >CR CRS common Infections higher 65.9% vs 16.8% Mostly Grade 1/2 Monitoring ICANS uncommon important * Markedly deeper remissions Safety profile consistent with with teclistamab established BCMA bispecific experience 08 What Changes in Practice? Teclistamab moves closer toward an earlier-line standard-of-care role in RRMM. Mina et al ASCO 2026

ASCO AMERICAN SOCIETY OF CLINICAL ONCOLOGY COI Management Member Directory Become Member Search a Sign In Meetings & Education Research & Data Practice & Patients Career Development News & Initiatives Get Involved Abstracts Guidelines Journal Articles Posters Slides Videos Home / Abstracts & Presentations / MajesTEC-9: A phase 3 rando... MajesTEC-9: A phase 3 randomized study of teclistamab monotherapy vs investigator's choice of pomalidomide, bortezomib, and dexamethasone or carfilzomib and dexamethasone (PVd/Kd) in patients (pts) with relapsed refractory multiple myeloma (RRMM).

ONC & Top 10 Anticipated Practice Changing/Informing Abstracts for #ASCO26 from Community Oncologists (@OncBrothers) perspective 1. #PlenarySession:#RASolute302 Ph-III, Daraxonrasib VS. Chemo in 2L metastatic Pancreatic Ductal Adenocarcinoma 2. #EPISODE3: Ph-III, Aspirin vs. Placebo in adjuvant settings after curative resection in Stage III Colorectal Cancer. 3. #PlenarySession: #LIBRETTO432 Ph-III, Selpercatinib vs. Placebo in adjuvant (post definitive therapy: surgery or radiation) RET-fusion positive Stage-IB-IIIA Non-small Cell Lung Cancer. 4. #PlenarySession: #HARMONi6: Ph-III, Ivonescimab + Chemo vs. Tislelizumab + Chemo in 1L advanced/metastatic squamous histology Non- small Cell Lung Cancer. 5. #PlenarySession: #PROTEUS Ph-III, PeriOp Apalutamide + ADT VS. ADT alone followed by radical prostatectomy in high risk localized or locally advanced Prostate Cancer. 6. #EV302 (Update): Ph-III, Enfortumab vedotin + Pembrolizumab (approved in December 2023) VS. Chemo in IL locally advanced or metastatic Bladder Cancer. 7. #PlenarySession: #SARC041 Ph-III, Abemaciclib VS. Placebo in advanced, recurrent, or metastatic Dedifferentiated Liposarcoma. 8. #persevERA: Ph-III, Giredestrant + Palbociclib VS. Letrozole + Palbociclib in HR+ HER2 negative metastatic Breast Cancer. (Press Release: Negative study) 9. #OrigAMI5: Ph-III, Amivantamab + Pembro + Chemo VS. Pembro + Chemo in 1L recurrent or metastatic Head and Neck Squamous Cell Cancer. 10. #MajesTEC9 Ph-III, Teclistamab monotherapy VS. PVd/Kd and #SUCCESSOR2 Ph-III, Mezigdomide + Kd VS. Kd in relapsed refractory Multiple Myeloma. www.oncbrothers.com D @Oncbrothers

NEW YORK--(BUSINESS WIRE)- Pfizer Inc. (NYSE: PFE) today announced positive topline results from the Phase 3 MagnetisMM-5 study evaluating ELREXFIO® (elranatamab) as monotherapy in adults with relapsed or refractory multiple myeloma (RRMM) who received at least one prior line of treatment. The study demonstrated a statistically significant and clinically meaningful improvement in the primary endpoint of progression-free survival (PFS), as assessed by blinded independent central review (BICR), versus standard-of-care daratumumab plus pomalidomide and dexamethasone (DPd). The safety and tolerability of ELREXFIO was consistent with its known safety profile.

MajesTEC-9 Study Design1,2 Key Inclusion Criteria ≥18 years of age with documented MM Teclistamab Screening (28 days) RRMM per IMWG criteria with evidence of progressive disease or failure to achieve a R (1:1)a response to the last LOT EOT visit ECOG PS of 0-2 1-3 prior LOT, including ≥2 consecutive cycles of an anti-CD38 mAb and lenalidomide PVd or Kdb Key Exclusion Criteria Prior BCMA targeted therapy Primary Endpoints PFS CRS by severity Secondary Endpoints Efficacy PRO and HRQoL Analysis Overall response (≥PR) Change from baseline in HRQoL outcomes ≥VGPR Time to worsening in symptoms, functioning, and ≥CR overall HRQoL OS Proportion of patients with meaningful HRQoL PFS and depth of response in patients with improvement high-risk molecular features TTNT PK/PD Analysis Teclistamab serum concentrations Safety Presence of ADAs to teclistamab Incidence and severity of AEs; SAEs